The Division of Rheumatology strives to understand more about rheumatoid arthritis (RA) through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
Bristol-Myers Squibb Research IRB# 21-3663 PI- Christopher Striebich | Study to compare the response to treatment with subcutaneous Abatacept vs Adalimumab on background methotrexate in adults with early, seropositive rheumatoid arthritis who have "shared epitope" HLA Class II risk alleles and have an inadequate response to methotrexate | Basic Eligibility:
| 303-724-0581 Karen.Franklin@CUAnschutz.edu |
Interdisciplinary Joint Biology Program for Rheumatic and Orthopedic Diseases 20-1908 Larry Moreland, MD | The goal of the University of Colorado Interdisciplinary Joint Biology Program is to employ cutting edge science and technology to advance the research of inflammatory, degenerative and musculoskeletal joint diseases. | Individuals with RA, SpA, PsA, AS, OA or any other form of inflammatory arthritis with active disease in their elbow, wrist, hand joints, knee, ankle or shoulder and are willing to undergo a synovial biopsy at that site or individuals who are having an orthopedic surgery and are willing to donate their tissues that would normally be discarded | 303-724-7541 Jennifer.Seifert@CUanschutz.edu Or visit https://medschool.cuanschutz.edu/cuijbp |
Platelet Function in RA 20-2318 Pavel
Davizon-Castillo, MD; PI | A study to learn more about platelet function in people with RA pre Anti-TNF and post Anti-TNF. Visit consists of consent and 2 additional tubes drawn during regular clinic visit. No additional questionnaires collected. |
| 303-724-7510 Marie.Feser@CUAnschutz.edu |
CPIRA-2 20-2619 Kevin Deane, MD | A study designed to learn more about pain in early Rheumatoid Arthritis. It’s a 1 year study with 3 visits (baseline, 3 months, 1 year). | Individuals with Rheumatoid Arthritis for less than 6 months may be eligible | 303-724-7510 Marie.Feser@CUAnschutz.edu |
MINERAL; Microbiome and Neutrophil associated factors in Rheumatoid Arthritis and Autoimmune-related Interstitial Lung Disease 20-2769 Melissa Griffith, MD | An observational study to investigate the causes of chronic lung disease in rheumatoid arthritis and other autoimmune diseases | 1. At least 18 years old 2. Falls under one of the following criteria: a. Diagnosis of scleroderma b. Diagnosis of idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia with autoimmune features (IPAF) c. Diagnosis of RA with associated interstitial lung disease d. Diagnosis of RA with previous lung abnormalities seen on lung scan | 303-724-0071 Kasey.Bales@CUAnschutz.edu or click here to give your information to the study team. |
ALTRA 19-1150Kevin Deane, MD | To learn about the immune system and microbiome in individuals at risk for developing RA | Individuals with a positive blood test (anti-CCP antibody) or their close relatives (parents, siblings, children) | 303-724-8330 Or email rastudies@cuanschutz.edu Or visit website: www.altraproject.org |
SPARO Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins [SPARO] 20-0206 Kristen Demoruelle, MD, PhD | An observational study to investigate the lung as a potential site where rheumatoid arthritis (RA) is developed. | At least 18 years old Falls under one of the following criteria: 1) has a parent, sibling, or child who is diagnosed with RA 2) has a clinically confirmed RA diagnosis 3) no personal or family history of RA | 303-724-0071 Kasey.Bales@CUAnchutz.edu or click here to give your information to the study team. |
FIERA Female Influences on the Etiology of Rheumatoid Arthritis (FIERA) Study 14-1751 Kristen Demoruelle, MD, PhD | An observational study to identify the female genital tract as a potential mucosal site of initiation of autoimmunity in rheumatoid arthritis (RA). | Analysis on-going, but closed to recruitment |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.